PLENAXIS
LOE Approachingabarelix
NDAINTRAMUSCULARPOWDERPriority Review
Approved
Nov 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLENAXIS (abarelix) is a gonadotropin-releasing hormone (GnRH) antagonist administered as an intramuscular injection in powder form. It is indicated for men with advanced prostate cancer who require rapid testosterone suppression. The drug works by directly blocking GnRH receptors, leading to rapid suppression of luteinizing hormone and follicle-stimulating hormone, thereby reducing testosterone levels.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), this product is in managed decline; commercial teams are likely focused on maximizing remaining exclusivity and preparing transition strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, PLENAXIS offers limited career growth opportunities and declining headcount visibility. This product represents a maintenance portfolio assignment rather than a high-impact career move.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.